All In Biotech

Drug Trial Radar · NCT07277660

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

165

Actual

Start

Dec 29, 2025

Primary completion

May 17, 2027

Study completion Mar 6, 2028

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Dec 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

Conditions

  • Atopic Dermatitis

Interventions

  • GalvokimigBiological

    Drug: Galvokimig Pharmaceutical form: Solution for injection

  • PlaceboDrug

    Drug: Placebo Pharmaceutical form: Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16Time frame: Week 16

Locations

59 sites in 9 countries. Site status is shown where the registry gives one.

  • Atd002 52021

    Oceanside, California

  • Atd002 52008

    Santa Monica, California

  • Atd002 52013

    Boca Raton, Florida

  • Atd002 52007

    Miami, Florida

  • Atd002 52003

    Miami, Florida

  • Atd002 52015

    Savannah, Georgia

  • Atd002 52017

    Chicago, Illinois

  • Atd002 52018

    Wheaton, Illinois

  • Atd002 52012

    New Albany, Indiana

  • Atd002 52014

    Bowling Green, Kentucky

  • Atd002 52009

    Troy, Michigan

  • Atd002 52010

    Omaha, Nebraska

  • Atd002 52022

    New York, New York

  • Atd002 52020

    The Bronx, New York

  • Atd002 52019

    Philadelphia, Pennsylvania

  • Atd002 52005

    Dallas, Texas

  • Atd002 52016

    Frisco, Texas

  • Atd002 52011

    Frisco, Texas

  • Atd002 52004

    Sugar Land, Texas

  • Atd002 41004

    Lovech, Bulgaria

  • Atd002 41001

    Pleven, Bulgaria

  • Atd002 41007

    Plovdiv, Bulgaria

  • Atd002 41002

    Sevlievo, Bulgaria

  • Atd002 41005

    Sofia, Bulgaria

  • Atd002 41006

    Sofia, Bulgaria

  • Atd002 51002

    Edmonton, Canada

  • Atd002 51006

    Hamilton, Canada

  • Atd002 51007

    Toronto, Canada

  • Atd002 51003

    Vancouver, Canada

  • Atd002 42002

    Náchod, Czechia

  • Atd002 42001

    Prague, Czechia

  • Atd002 42003

    Prague, Czechia

  • Atd002 42004

    Prague, Czechia

  • Atd002 42005

    Prague, Czechia

  • Atd002 43001

    Bad Bentheim, Germany

  • Atd002 43004

    Leipzig, Germany

  • Atd002 43007

    Mahlow, Germany

  • Atd002 44001

    Debrecen, Hungary

  • Atd002 21001

    Habikino, Japan

  • Atd002 21007

    Nagoya, Japan

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.